Vericel (US:VCEL)2026-02-26 14:00Financial Performance - Total revenue for 2025 reached $276,259,000, representing a 16.5% increase from $237,224,000 in 2024, driven primarily by MACI volume and price growth [346]. - MACI revenue increased to $239,506,000 in 2025, up 21.4% from $197,309,000 in 2024, while Epicel revenue decreased by 12.4% to $32,066,000 [347]. - Gross profit for 2025 was $205,599,000, a 19.5% increase from $172,107,000 in 2024 [346]. - The company experienced a significant increase in net income, reaching $16,518,000 in 2025, a 59.4% increase from $10,362,000 in 2024 [346]. Regulatory Approvals and Product Development - The FDA approved MACI's supplemental Biologics License Application in August 2024, allowing for arthroscopic delivery, which became commercially available in Q3 2024 [337]. - The MACI Arthro technique has generated strong interest, with over 900 surgeons participating in training programs, expanding the target surgeon base from 5,000 to 7,000 [337]. - The company received Investigational New Drug clearance for MACI's use in the ankle in Q2 2025, with a clinical trial (MASCOT) involving 309 subjects planned [338]. - NexoBrid revenue grew by 42.4% to $4,687,000 in 2025, up from $3,292,000 in 2024, following its FDA approval for pediatric patients in August 2024 [347]. - The company is pursuing regulatory approval for MACI in the UK, with plans to commercialize in 2027 if successful [339]. Manufacturing and Operational Changes - The Burlington manufacturing facility is expected to become the primary manufacturing site for MACI and Epicel, enhancing strategic flexibility for global commercialization [331]. - Gross profit for the year ended December 31, 2025, increased due to MACI revenue growth, with a primarily fixed manufacturing cost structure [349]. Expenses and Cash Flow - Research and development expenses rose to $27.6 million in 2025 from $24.8 million in 2024, mainly due to increased headcount and technical transfer costs [350]. - Selling, general and administrative expenses increased to $167.0 million in 2025 from $142.8 million in 2024, driven by higher employee expenses and marketing activities [351]. - Net cash provided by operating activities was $51.9 million in 2025, down from $58.2 million in 2024, primarily due to a net decrease in working capital accounts [356][357]. - Net cash used in investing activities was $43.9 million in 2025, compared to $79.0 million in 2024, reflecting investment purchases and property and equipment expenditures [360][361]. - Net cash provided by financing activities was $7.1 million in 2025, down from $19.1 million in 2024, due to lower proceeds from stock options [362][363]. Financial Obligations and Investments - The company has total remaining obligations related to operating and finance leases of $132.3 million as of December 31, 2025 [367]. - The company entered into a $150.0 million revolving credit agreement in July 2022, with no outstanding borrowings as of December 31, 2025 [366]. - Total purchase commitments related to raw materials and finished goods amounted to $15.8 million as of December 31, 2025 [369]. - The company recorded a full valuation allowance against its net deferred tax assets due to a three-year cumulative loss position and history of operating losses [384]. Risk Management - As of December 31, 2025, a 100 basis point unfavorable change in interest rates would have resulted in approximately a $0.9 million decrease in the fair value of the investment portfolio [387]. - The company had no borrowings outstanding under the Revolving Credit Agreement as of December 31, 2025, reducing exposure to interest rate fluctuations [388]. - The company is primarily exposed to foreign exchange risk with respect to recognized assets and liabilities due to vendors in countries outside the U.S., typically paid in Euros [390]. - The company does not currently use interest rate derivative instruments or hedging transactions to manage exposure to interest rate changes of its investments [387]. Accounting and Valuation - Stock-based compensation expense is estimated based on the fair value of common stock at the date of grant, with key assumptions including volatility and risk-free interest rate [383]. - The company evaluates potential credit risk exposure for accounts receivable and available-for-sale investment securities in accordance with ASC 326 [389]. - Lease payments included in the measurement of lease liability are comprised of fixed payments, excluding non-lease components [381]. - The lease term includes the non-cancellable period plus any additional periods covered by options that are reasonably certain to exercise [382]. - Recent accounting standards may have a significant impact on the company's business, as noted in the summary of significant accounting policies [386].